Psoriasis has various systemic comorbidities including psychiatric disorders. Due to limited experience of dermatologists, psychiatric comorbidities are often not adequately addressed or treated. Recently, the association between depression, a risk factor for suicidality, and psoriasis has become a topic of interest due to suicides occurring in patients on new therapies such as apremilast and brodalumab for the treatment of psoriasis. A systematic literature search was conducted to provide an overview for clinicians on the epidemiological relationship between depression and psoriasis. Although there seems to be higher prevalence of depression in patients with psoriasis compared to non-psoriatic patients, the estimated prevalence of the comorbidity varies greatly and does not necessarily correlate with severity of psoriasis. Given the clear increased risk and association of depression with psoriasis, it is plausible that depression is not directly linked with the apremilast or brodalumab, but rather with psoriasis itself.
RappS.R.FeldmanS.R.ExumM.L.FleischerA.B.J.ReboussinD.M.. Psoriasis causes as much disability as other major medical diseases.J Am Acad Dermatol.1999 Sep; 41(3 Pt 1): 401–7.
2.
de OliveiraM de FSPRochaBdeO.DuarteG.V.. Psoriasis: classical and emerging comorbidities.An Bras Dermatol.2015 Feb; 90(1): 9–20.
3.
PompiliM.InnamoratiM.TrovarelliS.Suicide risk and psychiatric comorbidity in patients with psoriasis.J Int Med Res.2016 Sep; 44(1 suppl): 61–6.
4.
MaginP.J.AdamsJ.HeadingG.S.PondC.D.. Patients with skin disease and their relationships with their doctors: a qualitative study of patients with acne, psoriasis and eczema.Med J Aust.2009 Jan 19;190(2): 62–4.
5.
RichardsH.L.FortuneD.G.WeidmannA.SweeneyS.K.T.GriffithsC.E.M.. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient.Br J Dermatol.2004 Dec; 151(6): 1227–33.
6.
PicardiA.AmerioP.BalivaG.Recognition of depressive and anxiety disorders in dermatological outpatients.Acta Derm Venereol.2004; 84(3): 213–7.
7.
McDonoughE.AyearstR.EderL.Depression and anxiety in psoriatic disease: prevalence and associated factors.J Rheumatol.2014 May; 41(5): 887–96.
8.
WoodruffP.W.HigginsE.M.duVivierA.W.WesselyS.. Psychiatric illness in patients referred to a dermatology-psychiatry clinic.Gen Hosp Psychiatry.1997 Jan; 19(1): 29–35.
9.
PicardiA.MazzottiE.PasquiniP.. Prevalence and correlates of suicidal ideation among patients with skin disease.J Am Acad Dermatol.2006 Mar; 54(3): 420–6.
10.
MenterA.PaulC.StevensR.M.DayR.M.ShahK.. Psychiatric Disorders and Depression Incidence with Apremilast an Oral Phosphodiesterase 4 Inhibitor: Pooled Analysis of the ESTEEM 1 and ESTEEM 2 Trials [Poster]. Poster presented at: 23rd Annual Meeting of the European Academy of Dermatology and Venereology (EADV); October 8–12, 2014; Amsterdam, The Netherlands.
11.
PappK.A.ReichK.PaulC.A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.Br J Dermatol.2016 Aug; 175(2): 273–86.
12.
BhutaniT.PatelT.KooB.NguyenT.HongJ.KooJ.. A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions.J Am Acad Dermatol.2013 Aug; 69(2): e79–88.
13.
LangleyR.G.FeldmanS.R.HanC.Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.J Am Acad Dermatol.2010 Sep; 63(3): 457–65.
14.
ParisiR.RutterM.K.LuntM.Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink.J Invest Dermatol.2015 Sep; 135(9): 2189–97.
15.
MattooS.K.HandaS.KaurI.GuptaN.MalhotraR.. Psychiatric morbidity in vitiligo and psoriasis: a comparative study from India.J Dermatol.2001 Aug; 28(8): 424–32.
16.
SchmittJ.FordD.E.. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample.J Eur Acad Dermatol Venereol.2010 Aug; 24(8): 885–92.
17.
ParnaE.AluojaA.KingoK.. Quality of life and emotional state in chronic skin disease.Acta Derm Venereol.2015 Mar; 95(3): 312–6.
18.
Sanchez-CarazoJ.L.Lopez-EstebaranzJ.L.GuisadoC.. Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study).J Dermatol.2014 Aug; 41(8): 673–8.
19.
HanC.LoflandJ.H.ZhaoN.SchenkelB.. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis.J Drugs Dermatol.2011 Aug; 10(8): 843–50.
20.
McDonoughE.AyearstR.EderL.Depression and anxiety in psoriatic disease: prevalence and associated factors.J Rheumatol.2014 May; 41(5): 887–96.
21.
YangY.KohD.KhooL.NyuntS.Z.NgV.GohC.L.. The psoriasis disability index in Chinese patients: contribution of clinical and psychological variables.Int J Dermatol.2005 Nov; 44(11): 925–9.
22.
HerediE.CsordasA.ClemensM.The prevalence of obesity is increased in patients with late compared with early onset psoriasis.Ann Epidemiol.2013 Nov; 23(11): 688–92.
23.
SchwandtA.BergisD.DappA.Psoriasis and Diabetes: A Multicenter Study in 222078 Type 2 Diabetes Patients Reveals High Levels of Depression.J Diabetes Res.2015; 2015: 792968.
24.
ConsoliS.M.RolhionS.MartinC.Low levels of emotional awareness predict a better response to dermatological treatment in patients with psoriasis.Dermatology.2006; 212(2): 128–36.
25.
RemrodC.SjostromK.SvenssonA.. Psychological differences between early- and late-onset psoriasis: a study of personality traits, anxiety and depression in psoriasis.Br J Dermatol.2013 Aug; 169(2): 344–50.
26.
RichardsH.L.FortuneD.G.ChongS.L.P.Divergent beliefs about psoriasis are associated with increased psychological distress.J Invest Dermatol.2004 Jul; 123(1): 49–56.
27.
SchmiederA.SchaarschmidtM-LUmarN.Comorbidities significantly impact patients’ preferences for psoriasis treatments.J Am Acad Dermatol.2012 Sep; 67(3): 363–72.
28.
MizaraA.PapadopoulosL.McBrideS.R.. Core beliefs and psychological distress in patients with psoriasis and atopic eczema attending secondary care: the role of schemas in chronic skin disease.Br J Dermatol.2012 May; 166(5): 986–93.
29.
DalgardF.J.GielerU.Tomas-AragonesL.The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries.J Invest Dermatol.2015 Apr; 135(4): 984–91.
30.
KimballA.B.LeonardiC.StahleM.Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).Br J Dermatol.2014 Jul; 171(1): 137–47.
31.
CohenB.E.MartiresK.J.HoR.S.. Psoriasis and the Risk of Depression in the US Population: National Health and Nutrition Examination Survey 2009–2012.JAMA Dermatol.2016 Jan; 152(1): 73–9.
32.
DowlatshahiE.A.WakkeeM.HeringsR.M.C.HollesteinL.M.NijstenT.. Increased antidepressant drug exposure in psoriasis patients: a longitudinal population-based cohort study.Acta Derm Venereol.2013 Sep 4;93(5): 544–50.
33.
KulkarniA.S.BalkrishnanR.CamachoF.T.AndersonR.T.FeldmanS.R.. Medication and health care service utilization related to depressive symptoms in older adults with psoriasis.J Drugs Dermatol.2004 Dec; 3(6): 661–6.
34.
KirbyB.RichardsH.L.MasonD.L.FortuneD.G.MainC.J.GriffithsC.E.M.. Alcohol consumption and psychological distress in patients with psoriasis.Br J Dermatol.2008 Jan; 158(1): 138–40.
35.
IskandarI.Y.K.AshcroftD.M.WarrenR.B.Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register.Br J Dermatol.2015 Aug; 173(2): 510–8.
36.
KormanN.J.ZhaoY.LiY.LiaoM.TranM.H.. Clinical symptoms and self-reported disease severity among patients with psoriasis - Implications for psoriasis management.J Dermatolog Treat.2015; 26(6): 514–9.
37.
SharmaN.KoranneR.V.SinghR.K.. Psychiatric morbidity in psoriasis and vitiligo: a comparative study.J Dermatol.2001 Aug; 28(8): 419–23.
38.
EgebergA.KhalidU.GislasonG.H.MallbrisL.SkovL.HansenP.R.. Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study.Br J Dermatol.2015 Aug; 173(2): 471–9.
39.
JensenP.AhlehoffO.EgebergA.GislasonG.HansenP.R.SkovL.. Psoriasis and New-onset Depression: A Danish Nationwide Cohort Study.Acta Derm Venereol.2016 Jan; 96(1): 39–42.
40.
KimG.E.SeidlerE.KimballA.B.. A measure of chronic quality of life predicts socioeconomic and medical outcomes in psoriasis patients.J Eur Acad Dermatol Venereol.2015 Feb; 29(2): 249–54.
41.
AlShahwanM.A.. The Prevalence of Anxiety and Depression in Arab Dermatology Patients.J Cutan Med Surg.2015 Jun; 19(3): 297–303.
42.
ZachariaeR.ZachariaeC.O.C.LeiU.PedersenA.F.. Affective and sensory dimensions of pruritus severity: associations with psychological symptoms and quality of life in psoriasis patients.Acta Derm Venereol.2008; 88(2): 121–7.
43.
JacobiA.KupkeC.BehzadM.HertlM.. Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study.Int J Dermatol.2013 Sep; 52(9): 1081–7.
44.
MenegonD.B.PereiraA.G.CamerinA.C.CestariT.. Psoriasis and comorbidities in a southern Brazilian population: a case-control study.Int J Dermatol.2014 Nov; 53(11): e518–525.
45.
SchmittJ.FordD.E.. Under standing the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis - a structural equations modeling approach.Gen Hosp Psychiatry.2007 Apr; 29(2): 134–40.
Attah JohnsonF.Y.MostaghimiH.. Co-morbidity between dermatologic diseases and psychiatric disorders in Papua New Guinea.Int J Dermatol.1995 Apr; 34(4): 244–8.
48.
AkayA.PekcanlarA.BozdagK.E.AltintasL.KaramanA.. Assessment of depression in subjects with psoriasis vulgaris and lichen planus.J Eur Acad Dermatol Venereol.2002 Jul; 16(4): 347–52.
49.
EspositoM.SaracenoR.GiuntaA.MaccaroneM.ChimentiS.. An Italian study on psoriasis and depression.Dermatology.2006; 212(2): 123–7.
50.
MoradiM.RenczF.BrodszkyV.MoradiA.BaloghO.GulacsiL.. Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey.Arch Iran Med.2015 Mar; 18(3): 153–9.
51.
HelmickC.G.Lee-HanH.HirschS.C.BairdT.L.BartlettC.L.. Prevalence of psoriasis among adults in the U.S.: 2003–2006 and 2009–2010 National Health and Nutrition Examination Surveys.Am J Prev Med.2014 Jul; 47(1): 37–45.
52.
KurdS.K.TroxelA.B.Crits-ChristophP.GelfandJ.M.. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.Arch Dermatol.2010 Aug; 146(8): 891–5.
53.
WuY.MillsD.BalaM.. Psoriasis: cardiovascular risk factors and other disease comorbidities.J Drugs Dermatol.2008 Apr; 7(4): 373–7.
54.
DommaschE.D.LiT.OkerekeO.I.LiY.QureshiA.A.ChoE.. Risk of depression in women with psoriasis: a cohort study.Br J Dermatol.2015 Oct; 173(4): 975–80.
55.
TsaiT-FWangT-SHungS-TEpidemiology and comorbidities of psoriasis patients in a national database in Taiwan.J Dermatol Sci.2011 Jul; 63(1): 40–6.
56.
Zeljko-PenavicJ.SitumM.BabicD.SimicD.. Analysis of psychopathological traits in psoriatic patients.Psychiatr Danub.2013 Jun; 25 Suppl 1: 56–9.
57.
AkM.HaciomerogluB.TuranY.Temperament and character properties of male psoriasis patients.J Health Psychol.2012 Jul; 17(5): 774–81.
58.
KilicA.GulecM.Y.GulU.GulecH.. Temperament and character profile of patients with psoriasis.J Eur Acad Dermatol Venereol.2008 May; 22(5): 537–42.
59.
LeiboviciV.CanettiL.YahalomiS.Well being, psychopathology and coping strategies in psoriasis compared with atopic dermatitis: a controlled study.J Eur Acad Dermatol Venereol.2010 Aug; 24(8): 897–903.
60.
Martinez-GarciaE.Arias-SantiagoS.Valenzuela-SalasI.Garrido-ColmeneroC.Garcia-MelladoV.Buendia-EismanA.. Quality of life in persons living with psoriasis patients.J Am Acad Dermatol.2014 Aug; 71(2): 302–7.
61.
Molina-LeyvaA.Almodovar-RealA.CarrascosaJC-RMolina-LeyvaI.Naranjo-SintesR.Jimenez-MoleonJ.J.. Distribution pattern of psoriasis, anxiety and depression as possible causes of sexual dysfunction in patients with moderate to severe psoriasis.An Bras Dermatol.2015 Jun; 90(3): 338–45.
62.
KotruljaL.TadinacM.Joki-BegiN.A.GregurekR.. A multivariate analysis of clinical severity, psychological distress and psychopathological traits in psoriatic patients.Acta Derm Venereol.2010 May; 90(3): 251–6.
63.
Devrimci-OzguvenH.KundakciT.N.KumbasarH.BoyvatA.. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients.J Eur Acad Dermatol Venereol.2000 Jul; 14(4): 267–71.
64.
KarababaF.YesilovaY.TuranE.SelekS.AltunH.SelekS.. Impact of depressive symptoms on oxidative stress in patients with psoriasis.Redox Rep.2013; 18(2): 51–5.
65.
BilgicA.BilgicO.AkisH.K.EskiogluF.KilicE.Z.. Psychiatric symptoms and health-related quality of life in children and adolescents with psoriasis.Pediatr Dermatol.2010 Dec; 27(6): 614–7.
66.
KourisA.ChristodoulouC.StefanakiC.Quality of life and psychosocial aspects in Greek patients with psoriasis: a cross-sectional study.An Bras Dermatol.2015 Dec; 90(6): 841–5.
67.
RemrodC.SjostromK.SvenssonA.. Subjective stress reactivity in psoriasis - a cross sectional study of associated psychological traits.BMC Dermatol.2015 May 2;15: 6.
68.
RichterP.WernerJ.HeerleinA.E.KrausA.SauerH.. On the validity of the Beck Depression Inventory.Psychopathology.1998 May; 31(3): 160–8.
69.
BjellandI.DahlA.A.HaugT.T.NeckelmannD.. The validity of the Hospital Anxiety and Depression Scale. An updated literature review.J Psychosom Res.2002 Feb; 52(2): 69–77.
70.
KroenkeK.SpitzerR.L.WilliamsJ.B.. The PHQ-9: validity of a brief depression severity measure.J Gen Intern Med.2001 Sep; 16(9): 606–13.
71.
KimballA.B.LeonardiC.StahleM.Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).Br J Dermatol.2014 Jul; 171(1): 137–47.
72.
PujolR.M.PuigL.DaudenE.Mental health self-assessment in patients with moderate to severe psoriasis: an observational, multicenter study of 1164 patients in Spain (the VACAP Study).Actas Dermosifiliogr.2013 Dec; 104(10): 897–903.
73.
RyanC.KormanN.J.GelfandJ.M.Research gaps in psoriasis: opportunities for future studies.J Am Acad Dermatol.2014 Jan; 70(1): 146–67.
74.
GuptaM.A.SchorkN.J.GuptaA.K.KirkbyS.EllisC.N.. Suicidal ideation in psoriasis.Int J Dermatol.1993 Mar; 32(3): 188–90.
75.
de OliveiraP.S.S.CardosoP.R.G.Lima EV deA.IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-Type Psoriasis in Brazilian Patients.Mediators Inflamm.2015; 2015: 819149.
76.
DavamiM.H.BaharlouR.Ahmadi VasmehjaniA.Elevated IL-17 and TGF-beta Serum Levels: A Positive Correlation between T-helper 17 Cell-Related Pro-Inflammatory Responses with Major Depressive Disorder.Basic Clin Neurosci.2016 Apr; 7(2): 137–42.
77.
Celgene Corporation press release.Oral Otezla® (apremilast) approved by the U.S. Food and Drug Administration for the treatment of patients with moderate to severe plaque psoriasis. September 23, 2014. http://ir.celgene.com/releasedetail.cfm?ReleaseID=872240. Accessed October 20, 2016.
MenterA.PaulC.StevensR.M.DayR.M.ShahK.. Psychiatric Disorders and Depression Incidence with Apremilast an Oral Phosphodiesterase 4 Inhibitor: Pooled Analysis of the ESTEEM 1 and ESTEEM 2 Trials [Poster]. Poster presented at: 23rd Annual Meeting of the European Academy of Dermatology and Venereology (EADV); October 8–12, 2014; Amsterdam, The Netherlands.
81.
CrowleyJ.WollenhauptJ.ReichK.ShahK.ChenR.MeaseP.J.. Long-term Safety in Psoriasis and Psoriatic Arthritis Patients Treated With Apremilast: Pooled Analysis for 156 Weeks in the ESTEEM and PALACE 1–3 Phase 3 Trials [Poster]. Poster presented at: 25th Congress of the European Academy of Dermatology and Venereology (EADV); September 28-October 2, 2016; Vienna, Austria.
82.
KavanaughA.AdebajoA.O.GladmanD.D.Long-term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1) [Poster]. Poster presented at: 79th Annual Scientific Meeting of the American College of Rheumatology (ACR) and the 49th Annual Meeting of the Association of Rheumatology Health Professionals (ARHP); November 6–11, 2015; San Francisco, CA, USA.
ChiricozziA.RomanelliM.SaracenoR.TorresT.. No meaningful association between suicidal behavior and the use of.Expert Opin Drug Saf.2016 Dec; 15(12): 1653–9.
86.
Siliq™ [prescribing information].Valeant Pharmaceuticals North America LLC.Bridgewater, NJ; 2017.
